摘要
目的 探讨急性髓系白血病（AML）的免疫表型特点及其与疗效的关系.方法 采用流式细胞术（FCM）对96例初诊的AML患者进行免疫表型检测.结果 96例AML患者髓系抗原表达依次为CD13 97.92％（94/96）,CD11789.58％（86/96）,CD33 82.29％（79/96）.干/祖细胞分化抗原表达依次为CD38 95.83％（92/96）,HLA-DR 75.00％（72/96）,CD34 62.5％（60/96）.而M3极少表达CD34及HLA-DR.CD14只在M4及M5中表达.淋系抗原在AML患者中也有阳性表达,其中CD4 37.5％（36/96）,CD722.92％（22/96）,CD2 10.42％（10/96）.对其中46例患者进行疗效分析,总完全缓解（CR）率为67.39％（31/46）.CD33、CD1t7、CD1tb、CD14、CD64、CD4、CD34、HLA-DR等抗原表达阳性组与阴性组间CR率差异无统计学意义（确切概率法,均P＞0.05）.但CD7阳性患者CR率明显低于阴性者,差异有统计学意义（确切概率法,P＜0.05）.结论 CD33、CD17、CD117是AML最常见的免疫标志3伴CD7阳性表达的AML患者对化疗反应差.
Objective To investigate the immunophenotypic characteristics of acute myeloid leukemia （AML）and its relationship with chemotherapy response.Methods The immunophenotyping was performrd by flow cytometry in 96 newly diagnosed AML patients.Results In 96 patients with AML,the myeloid antigens were mainly expressed including CD13（94/96,97.92％）,CD117（86/96,89.58％）,CD33（79/96,82.29％）respectively.The positive expression of stem/progenitor cell differentiation antigens were CD38 （92/96,95.83％）,HLA-DR（72/96,75.00％）and CD34（60/96,62.50％）.While CD34 and HLA-DR were fewly expressed in M3.The CD14 was only expressed in M4 and M5.The lymphocytic antigens had positive expression in the patients with AML,in which CD4 was 37.5％（36/96）,CD7 was 22.92％（22/96）and CD2 was 10.42 ％（10/96）.In 46 patients for treatment response analysis,total CR rate was 67.39％（31 /46）.There was no significant difference of CR rates between the antigens positive group and negative group including CD33,CD117,CD11b,CD14,CD64,CD4,CD34 and HLA-DR.However,the CR rate was significantly lower in CD7 positive cases than CD7 negative ones,with statistically significance difference（P=0.01）.Conclusions CD13,CD33and CD117 are the most common antigens in AML.The patients with the positive expression of CD7 have poor response to chemotherapy in AML.
出处
《白血病．淋巴瘤》
CAS
2013年第10期597-599,共3页
Journal of Leukemia & Lymphoma
